-
03/03/2024anemptytextllineiLEADS BMS presents the effects of its novel FXR agonist in Physiogenex's ALD/MetALD hamster... -
01/30/2024anemptytextllineHepaRegenix publishes data on first in class MKK4 inhibitors demonstrating benefits in Physiogenex CCl4... -
12/04/2023anemptytextllineiLeads BMS publishes a new manuscript about its novel FXR agonist in Physiogenex's obese... -
11/23/2023anemptytextllinePhysiogenex will be presenting its innovative obese MetALD hamster model at the 7th Obesity... -
11/06/2023anemptytextllinePhysiogenex will be presenting a novel obese NASH hamster model of MetALD (Metabolic Dysfunction-Associated... -
11/06/2023anemptytextllinePhysiogenex is a proud sponsor of the Hanson Wade 7th IPF Summit to be... -
08/29/2023anemptytextllinePhysiogenex will be presenting a new NASH hamster study at the 10th Aging Research... -
06/17/2023anemptytextllinePhysiogenex will be presenting a new DIABETIC NASH HFpEF hamster study at the 83rd... -
05/30/2023anemptytextllinePhysiogenex is a proud sponsor of the Hanson Wade 1st Type 2 diabetes &... -
05/11/2023anemptytextllinePhysiogenex will be attending Biomed Israël 2023 annual meeting in Tel Aviv, May 16... -
05/11/2023anemptytextllinePhysiogenex, a leading preclinical contract research organization specialized in metabolic diseases and complications, and... -
04/19/2023anemptytextllinePhysiogenex and its subsidiary company Cardiomedex will be presenting a new diabetic NASH HFpEF... -
03/28/2023anemptytextllinePhysiogenex, its subsidiary company Cardiomedex, and its partner CLEA Japan Inc., will be presenting... -
03/15/2023anemptytextllinePhysiogenex will be presenting its innovative obese NASH hamster model at the NAFLD/NASH Keystone... -
03/06/2023anemptytextllinePhysiogenex is a proud sponsor of the Hanson Wade 5th CKD Summit to be... -
02/27/2023anemptytextllinePhysiogenex will be presenting its innovative obese NASH hamster model at the Global NASH... -
01/18/2023anemptytextllinePhysiogenex will be presenting its innovative obese NASH hamster model at the 2nd HFpEF... -
12/27/2022anemptytextllinePhysiogenex is delighted to be awarded ISO 9001:2015, a globally recognized certification of quality... -
11/29/2022anemptytextllinePhysiogenex will be presenting its innovative obese NASH hamster model at the 20th World... -
11/22/2022anemptytextllinePhysiogenex will be presenting its innovative obese MetALD hamster model at the 7th Obesity...
-
11/08/2022anemptytextllinePhysiogenex will be presenting its innovative obese NASH hamster model at the AFDD (AntiFibrotic... -
10/28/2022anemptytextllinePhysiogenex will be presenting 2 novel studies in its innovative obese NASH hamster model... -
10/14/2022anemptytextllinePhysiogenex will be presenting the effects of clinical benchmarks in its innovative obese NASH... -
09/27/2022anemptytextllinePhysiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in... -
09/15/2022anemptytextllinePhysiogenex will be exhibiting at booth#D04 and presenting 2 oral abstracts at the EASD... -
08/30/2022anemptytextllinePhysiogenex will be presenting a new DIO mouse study at the 9th Aging Research...
-
08/25/2022anemptytextllinePhysiogenex and its subsidiary company Cardiomedex will be presenting their original preclinical models during... -
06/21/2022anemptytextllinePhysiogenex will be exhibiting at booth#51 and presenting a new DIO-NASH mouse study (abstract#258)... -
06/10/2022anemptytextllinePhysiogenex will be presenting the effects of clinical benchmarks in its innovative obese NASH... -
06/02/2022anemptytextllinePhysiogenex will be presenting a new DIO-NASH mouse study at the 82nd Scientific Sessions... -
05/23/2022anemptytextllinePhysiogenex will be presenting the cardiometabolic benefits of clinical benchmarks in its innovative obese... -
05/13/2022anemptytextllinePhysiogenex will be presenting its two obese/type 2 diabetic rat models of nephropathy at... -
05/03/2022anemptytextllinePhysiogenex will be presenting the effects of SARS-CoV-2 infection on dyslipidemia and NASH in... -
04/19/2022anemptytextllinePhysiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in... -
04/04/2022anemptytextllinePhysiogenex will be presenting a poster at the Keystone Symposia - Lessons from the... -
03/29/2022anemptytextllinePhysiogenex will be presenting an e-Poster at the 31st conference of the Asian Pacific... -
03/17/2022anemptytextllinePhysiogenex invites you to attend its new webinar presented by our expert Dr. François Briand... -
01/19/2022anemptytextllineFrançois Briand, Director of Research and Business Development at Physiogenex, will be giving a... -
01/01/2022anemptytextllinePhysiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in... -
11/24/2021anemptytextllinePhysiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type... -
09/07/2021anemptytextllinePhysiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type... -
08/26/2021anemptytextllinePhysiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type... -
06/03/2021anemptytextllinePhysiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type... -
01/06/2021anemptytextllineIn collaboration with Institut Pasteur de Lille and the Center for Infection & Immunity... -
12/15/2020anemptytextllinePhysiogenex is proud to partner with the Digital 4th Annual NASH Summit (Dec. 16-17,... -
02/20/2020anemptytextllineThe 3-week NASH mouse, a rapid preclinical model of NASH, to be presented at... -
01/30/2020anemptytextllinePhysiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type... -
01/24/2020anemptytextllineThe SDT fatty rat, a model of diabetic nephropathy, to be presented at the... -
01/10/2020anemptytextllinePhysiogenex will be presenting its innovative NASH animal models on January 10th-11th, 2020 at... -
11/27/2019anemptytextllinePhysiogenex presented a poster on Monday, November 11th, 2019 at the AASLD Liver Meeting... -
11/07/2019anemptytextllineENGLISH VERSION Brand new facilities for Physiogenex! In September, we celebrated the inauguration of our new... -
11/04/2019anemptytextllinePhysiogenex will be presenting a poster on Tuesday, November 5th, 2019 from 12pm to... -
05/31/2019anemptytextllinePhysiogenex will be presenting a poster on Monday, June 10, 2019 12:00 PM –... -
05/17/2019anemptytextllinePhysiogenex will attend the 2019 EAS Congress on May 26-29, 2019 in Maastricht. Dr. François... -
04/17/2019anemptytextllinePhysiogenex will attend the 2019 edition of the NASH Annual Summit on April 23... -
04/08/2019anemptytextllinePhysiogenex will be present at the Keystone Symposia Immunometabolism, Metaflammation and Metabolic Disorders meeting... -
04/03/2019anemptytextllinePhysiogenex will attend The International Liver Congress on April 12, 2019 during the Poster... -
02/25/2019anemptytextllinePhysiogenex will attend the Keystone Unraveling the Secrets of Kidney Disease meeting on March... -
02/14/2019anemptytextllinePhysiogenex will be present at the 28th Annual meeting of the Asian Pacific Association... -
02/06/2019anemptytextllinePhysiogenex will present at the Keystone Symposia Obesity and Adipose Tissue Biology, on February...
-
01/21/2019anemptytextllinePhysiogenex will present at the Keystone NASH and NAFLD in Santa Fe, NM, USA, January...
-
01/02/2019anemptytextllinePhysiogenex will present at the NASH-TAG 2019 in Park City, UT, USA, January 3rd-5th, 2019. Dr....
-
11/29/2018anemptytextllinePhysiogenex will be presenting radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at... -
11/14/2018anemptytextllinePhysiogenex will be presenting the effects of green coffee and green tea at the Obesity... -
11/08/2018anemptytextllinePhysiogenex will be presenting its 3-week ultra-fast NASH screening mouse model mouse at the Liver Meeting 2018,... -
10/26/2018anemptytextllinePhysiogenex will be presenting its innovative animal models of diabetic nephropathy, namely the db/db... -
10/07/2018anemptytextllinePhysiogenex will be presenting a hyperinsulinemic euglycemic clamp study differentiating insulin analogues in STZ-rats,...
-
09/14/2018anemptytextllinePhysiogenex will be presenting a study dealing with the effects of obeticholic acid and... -
06/23/2018anemptytextllinePhysiogenex will be presenting a hyperinsulinemic euglycemic clamp study differentiating insulin analogues in STZ-rats,...
-
06/10/2018anemptytextllineDuring the poster session, Physiogenex will be presenting a study dealing with the effects... -
05/10/2018anemptytextllinePhysiogenex will be presenting a study dealing with the effects of evolocumab, an anti-PCSK9... -
04/26/2018anemptytextllinePhysiogenex, Iris Pharma and CLEA Japan will be presenting the features of diabetic retinopathy... -
04/11/2018anemptytextllinePhysiogenex will present at the EASL - International Liver Congress 2018 in Paris, on April... -
03/12/2018anemptytextllinePhysiogenex will present at the APASL 2018 in New Delhi, India, March 14th-18th, 2018. Dr. François... -
01/18/2018anemptytextllinePhysiogenex will present at the Keystone Symposia on Obesity and NAFLD in Keystone, CO, USA,...
-
01/05/2018anemptytextllinePhysiogenex will present at the NASH-TAG 2018 in Park City, UT, USA, January 4th-6th, 2018. Dr....
CONTACT US FOR MORE INFORMATION